Show Notes
Traditional skin allergy patch testing can be cumbersome and time-intensive, often requiring multiple clinic visits. Mayo Clinic physicians have developed an emerging technology, allowing patients to capture photos of their skin. Through the power of an app, the providers have the ability to accurately analyze and assess the results. This approach eliminates the need for multiple clinc visits, saving time for both patients and clinicians. Also, an AI algorithm is able to detect differences in skin color, providing more accurate and personalized results. Learn how this cutting-edge technology is making patch testing easier, reliable, and more accessible for everyone. The episode features Charles Bruce, M.B., Ch.B., the chief innovation officer at Mayo Clinic in Florida, and Alison Bruce, M.B., Ch.B., dermatologist.Get the latest health information from Mayo Clinic's experts, subscribe to Mayo Clinic’s newsletter for free today: https://mayocl.in/3EcNPNc
More from Tomorrow's Cure
How could Mayo Clinic’s Global AI Platform transform personalized care?
What if transplant patients could one day live free from lifelong anti-rejection drugs?
What happens when multiple sclerosis symptoms mask a different condition?
What if repairing damaged cartilage could be done in a single procedure? Using your own cells and the healing signals they need to recover?
What if the milk you are drinking could help fight cancer? In this episode of Tomorrow's Cure, we explore cholangiocarcinoma and a surprising new approach to targeting it using milk‑derived nanoparticles and precision aptamer‑based delivery. Host Lindsey Seavert is joined by surgical oncologist Dr. Rory Smoot and long‑term survivor and advocate Melinda Bachini to unpack why this cancer is so challenging, what symptoms and treatment paths patients typically face, and how emerging gene‑delivery platforms and AI‑driven discovery are opening new possibilities when standard therapies fall short. Through Melinda’s 16‑year survivorship story and Dr. Smoot’s lab work that literally starts with skim milk from the Mayo Clinic cafeteria, listeners hear how “chemical antibodies” called aptamers can act as molecular keys to deliver therapy directly to cholangiocarcinoma cells, and how computational tools are accelerating the search for new targets. Together, they discuss the emotional and practical realities of living at the edge of what medicine can do today, the expanding landscape of clinical trials, and why innovation in this rare cancer may ripple out to colon, lung and other hard‑to‑treat tumors.